Pleasanton, Calif.-based biotechnology startup 10x Genomics went public on Sept. 12, opening on the Nasdaq Stock Market at a price of $39 per share. The company’s initial public offering price was ...
With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.
Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and ...
10x Genomics made its first acquisition Aug. 28, with the purchase of Epinomics, a startup developing technologies for epigenetics research. Epigenetics is the study of changes in an organism’s DNA ...
Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results